There is no "switching" needed—Mounjaro IS tirzepatide
The patient is already on tirzepatide 15 mg (Mounjaro) and should simply continue at 15 mg weekly. This appears to be a misunderstanding of medication nomenclature: Mounjaro is the brand name for tirzepatide used for diabetes, while Zepbound is the brand name for tirzepatide used for obesity—but they are the exact same medication 1.
Key Points to Clarify
If the patient is already tolerating 15 mg of Mounjaro weekly, they should continue at 15 mg. There is no need to restart at a lower dose or "switch" to anything, as they are already on the maximum approved dose of tirzepatide 2, 1.
If This is Actually a Brand Switch (Mounjaro to Zepbound)
- Continue at 15 mg weekly if switching between brand names for insurance or formulary reasons
- The dosing, formulation, and medication are identical 1
- No dose adjustment or re-titration is necessary
If the Patient Has Been Off Tirzepatide for an Extended Period
If treatment was discontinued or paused for a significant length of time, restart at 2.5 mg weekly and re-titrate. The 2025 AACE guidelines explicitly state that patients who discontinue or pause GLP-1 RA-based therapies need to restart at a low dose and titrate up to allow the body time to acclimate to the medication 2.
The standard titration schedule is:
- Start: 2.5 mg weekly (initiation dose, not for glycemic control)
- Week 4: Increase to 5 mg weekly
- Subsequent increases: 2.5 mg increments every 4 weeks as tolerated
- Maximum: 15 mg weekly 1
Common Pitfall to Avoid
Do not confuse brand names with different medications. Mounjaro and Zepbound are both tirzepatide—the only difference is the FDA-approved indication (diabetes vs. obesity) and potentially the packaging. The active ingredient, dosing schedule, and formulation are identical 2, 1.
If Switching FROM Another GLP-1 RA TO Tirzepatide
If the question actually meant switching from a different GLP-1 RA (like semaglutide) to tirzepatide:
Start tirzepatide at 2.5 mg weekly regardless of the prior GLP-1 RA dose. Even patients on semaglutide 1.0-2.4 mg or dulaglutide 4.5 mg should begin tirzepatide at the 2.5 mg initiation dose 1, 3, 4. The SURPASS-SWITCH trial demonstrated that patients switching from dulaglutide (including those on 1.5 mg) who started at 2.5 mg and titrated to 15 mg achieved superior glycemic control and weight loss compared to dose escalation of their original medication 3, 4.
One small study suggested that early escalation to 10 mg may be beneficial for patients switching from semaglutide 1.0 mg who had inadequate response, but this is not standard practice and the FDA-approved dosing remains 2.5 mg initiation 5.